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Identity 
Other names: CD148; DEP1; HPTPeta; R-PTP-ETA; 
SCC1 
HGNC (Hugo): PTPRJ 
Location: 11p11.2 




Gene ENSG00000149177 has 24 alternate exons. 
Transcription 
Multiple transcript variants encoding different isoforms 
have been found for this gene. Three transcripts are 
described in Ensembl (ID: ENSG00000149177).  
The first (ENST00000418331) represents the longer 
isoform and encodes a protein that consists of an 
extracellular fibronectin type 3 domain and a cytosolic 
catalytic domain. The second isoform 
(ENST00000440289) has multiple differences in the 
presence and absence of exons at its 3' end, compared 
to the first isoform. These differences produce a uniq e 
3' UTR and the encoded protein is shorter and consists 
of the extracellular fibronectin type 3 domain without 
the cytosolic catalytic region. The third transcript 
(ENST00000278456) has the same length as the first, 
but it encodes a truncated protein, that consists of 
fibronectin type 3 domains. Only the first two isoforms 
are members of the human CCDS set and have been 
described in NCBI (IDs: NM_001098503.1, 
NM_001098503.1). 
The cDNA encoding PTPRJ/DEP-1 was isolated from 
a HeLa cell library (Ostman et al., 1994). The 
expression level and the activity of DEP-1 increase 
with cell density. This increase occurs gradually with 
increasing cell contact and is initiated before saturation 
cell density is reached. These observations suggest that 
DEP-1 may contribute to the mechanism of contact 
inhibition of cell growth. 
Protein 
 
DEP-1: location of SNPs and mutations reported in human 
cancer. DEP-1 sequence is according to UniProtKB/Swiss-
Prot: PTPRJ_HUMAN, Q12913. FNIII: Fibronectin domain, TM: 
Trans-membrane, KIM: Kinase Interaction Motif, PTP: Protein 
Tyrosine Phosphatase. 
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Description 
DEP-1 corresponds to a single-pass, type I membrane 
receptor-type protein tyrosine phosphatase; it is a 200-
250 kDa transmembrane molecule with a 35 residue 
signal peptide, 940 residue extracellular portion, 21 
residues in helical transmembrane region and 341 
aminoacids in the intracytoplasmic tail, with a single 
catalytic domain at the carbossi-terminus. 
The protein N-terminus has nine fibronectin type III 
(FNIII) repeats, contains 34 potential N-linked 
glycosylation sites and it was found glycosylated in 
seven asparagine residues by mass spectrometry (Liu et 
al., 2005; Chen et al., 2009). DEP-1 can dimerize 
(binding site 972-996) through the transmembrane 
domain (Chin et al., 2005) but it is unclear whether it 
can exist as dimers, physiologically. Sedimentation 
velocity measurements show that DEP1, along with 
other single-domain receptor phosphatases (e.g., IA2, 
IA2beta, GLEPP1 and STEP) is monomeric in solution 
(Barr et al., 2009). 
The regulation of receptor-like protein tyrosine 
phosphatases is generally poorly understood. Sorby et 
al. have identified MatrigelTM (a preparation of 
extracellular matrix proteins) as a source of DEP-1 
ligand(s) and agonist(s) (Sorby et al., 2001). 
Expression 
DEP-1 is expressed in several cell types, including 
endothelial, epithelial, and in all haematopoietic 
lineages. It was found to be present on many epithelial 
cell types with glandular and endocrine differentiation 
as well as on fibrocytes, melanocytes and Schwann 
cells (Autschbach et al., 1999). It is widely express d 
on B and T cells, granulocytes, macrophages, certain 
dendritic cells as well as mature thymocytes and it was 
shown to negatively regulate T cell receptor and 
terminating its response to stimulation. DEP-1 is 
thought to play a role in the down regulation of T cell 
activation and signalling, by interfering with the 
phosphorylation of Phospholipase C Gamma 1 and 
Linker for Activation of T Cells (LAT) and by reducing 
TCR-induced transcription factor NFAT (nuclear factor 
of activated T cells) (Lin and Weiss, 2003; Lin et al., 
2004; Zhu et al., 2008; Tangye et al., 1998; Baker et 
al., 2001). DEP-1 expression is regulated during T cell 
activation and is constitutive in autoimmune murine T 
cells. These expression data suggest that DEP-1 plays a 
regulatory role to control an immune response and the 
proposed model of action describes DEP-1 as excluded 
from the immunologic synapse (i.e., the site of APC 
and T cell contact) during early T cell-APC (Antigen 
Presenting Cell) interactions. After T cell-APC 
disengagement, DEP-1 is no longer excluded by the 
synapse and can access and dephosphorylate substrates 
to down-regulate prolongation of the response (Lin et 
al., 2004). 
It is interesting to note that the expression patterns of 
DEP-1 are different between humans and mice, where 
the expression in the T cell lineage is more restricted 
(Lin et al., 2004). Recently, DEP-1 is indicated as the 
phosphatase that can compensate for the absence of 
CD45, the prototypical receptor-like PTP expressed on 
immune cells (Zhu et al., 2008). 
Function 
DEP-1 is a member of the protein tyrosine phosphatase 
(PTP) family. Since its expression is increased with 
increasing cell density, it is strongly suggested that 
DEP-1 may contribute to the mechanism of contact 
inhibition of cell growth (Ostman et al., 1994). It seems 
to be involved in protein tyrosine kinase signaling, cell-
cell signaling, vasculogenesis and heart development 




Allelic loss of this gene is involved in thyroid 
carcinogenesis: the loss of heterozygosity (LOH) of 
PTPRJ is detected in 11/76 (14,5%) thyroid tumors 
(adenomas and carcinomas). DEP-1 overexpression in 
a malignant rat thyroid cell line was reported to 
specifically induce dephosphorylation of the Src-
inhibitory Y529 and thus to increase Src activity. In 
addition, there are data suggesting that PTPRJ 
polymorphisms can affect susceptibility to thyroid 
carcinomas: DEP-1 homozygous for the Gln276Pro, 
Arg326Gln and the Glu872Asp allele were more 
frequent in thyroid carcinoma patients than in healthy 
individuals. Moreover, PTPRJ LOH was more frequent 
in thyroid carcinomas of heterozygotes for Gln276Pro 
and Arg326Gln compared with homozygotes, 
suggesting that the presence of hemizygosity for these 
polymorphisms in the tumor facilitates tumor 
progression (Iuliano et al., 2004). It was recently 
reported that the homozygous genotype PTPRJ/DEP-1 
for Glu872Asp is associated with an increased risk to 
develop papillary thyroid carcinoma (Iuliano et al., 
2010). 
DEP-1 can dephosphorylate the single-pass 
transmembrane tyrosine kinase receptor RET, 
impairing its signaling. Iervolino et al. show that 
Tyr1062 is critical for the binding of RET to DEP-1 
and that DEP-1 can dephosphorylate the Tyr905 and 
Tyr1062 of the mutant RET bearing a germ-line 
Cys634Arg point mutation, responsible for the 
inheritance of multiple endocrine neoplasia types 2A 
(RET-MEN2A) and of the RET/PTC (papillary thyroid 
carcinoma) chimeric oncoprotein (Iervolino et al., 
2006). The authors also show a DEP-1 dose dependent 
reduction of the transforming activity of RET-MEN2A. 
Furthermore, Iervolino et al. verified that the 
conformationally altered RET, bearing the mutation 
Met918Threo, responsible for MEN2B, does not bind 
or is dephosphorylated by DEP-1. This resistance to 
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DEP-1 may account for the high oncogenic activity of 
the MEN2B RET alleles. 
The rat protein tyrosine phosphatase eta, homologue f 
DEP-1, suppresses the neoplastic phenotype of 
retrovirally transformed thyroid cell, causing G1 
growth arrest, by increasing the cyclin-dependent 
kinase inhibitor p27Kip1 protein level, through 
reduction of its proteasome-dependent degradation rate 
(Trapasso et al., 2000). 
Colon rectal cancer 
Note 
DEP-1 is a candidate human homologue of the mouse 
colon cancer susceptibility locus SCC1. 
Germline allele-specific epigenetic silencing of the 
gene PTPRJ, encoding DEP-1, is described in early-
onset familial colorectal cancer, due to a 170-kb 
intragenic duplication affecting the 5' end of the 
phosphatase gene PTPRJ the tandem duplication in a 
head-to-tail orientation (Venkatachalam et al., 2010; 
Ruivenkamp et al., 2002; Ruivenkamp et al., 2003a; 
Ruivenkamp et al., 2003b). PTPRJ is frequently deleted 
in human colon, lung and breast carcinomas or it show  
allelic imbalance in loss of heterozygosity (LOH) and 
missense mutations. LOH of PTPRJ occurs early in 
progressed colorectal adenoma. Ruivenkamp et al. 
(2002) identified 5 somatic missense mutations in the 
PTPRJ gene, in colon cancer. All are localized in the 
extracellular fibronectin domains, two, Arg214Cys and 
Arg326Gln, result in loss of a positive charge. Mita et 
al. show, in their association study, that the Arg326Gln 
SNP demonstrates a close association with colon rectal 
cancer risk (Mita et al., 2010). 
Nutrients, which are considered to be chemoprotectiv  
with respect to colon cancer development, including 
butyrate, green tea and apple polyphenols, seem to 
elevate transcription of endogenous DEP-1 mRNA and 
expression of DEP-1 protein. Upregulation of DEP-1 
expression with a consequent inhibition of cell growth 
and migration may present a mechanism of 




Suppressor of epithelial tumor. 
LOH of the PTPRJ gene are observed in average 38% 
of human meningiomas of all grades (Petermann et al., 
2010). Also, RNAi-mediated suppression of DEP-1, in 
DEP-1 positive meningioma cell lines (i.e., KT21, 
SF3061), causes enhanced motility and colony 
formation in semi-solid media (Petermann et al., 2010). 
It is therefore suggested that DEP-1 acts as a negativ  
regulator of PDGF signaling and as a positive regulator 
of adhesion signalling, cooperating in inhibition of cell 
motility and tumor invasiveness and behaving as a 
positive regulator of paxillin tyrosine phosphorylation 
in epithelial cells. DEP-1 negatively affects PDGF 
stimulated activation of inositol trisphosphate 
formation, Erk1/Erk2, p21Ras, and Src. Activation of 
receptor-associated PI3K activity and of Akt/PKB are 
weakly attenuated at early time points of PDGF 
stimulation (Jandt et al., 2003). PDGFR and DEP-1 
physically interact and there is a site-specific reduction 
in tyrosine phosphorylation of the PDGF b-receptor 
after in vivo and in vitro exposure to DEP-1. In fact, 
DEP-1 dephosphorylates the PDGFb-receptor P-
Tyr751 and P-Tyr1009/1021, which are required for 
activation of PI3-K and PLCgamma, respectively, 
while the PDGFR regulatory P-Tyr857 is less affected 
(Kovalenko et al., 2000). Moreover, DEP-1 interacts 
with and dephosphorylates the p85 subunit of PI3K, 
bound to PDGFR (Tsuboi et al., 2008). 
Various cancers 
Note 
EGFR and DEP-1 
EGFR and DEP-1 physically associate, and EGFR 
phosphorylates a substrate-trapping mutant of DEP-1. 
Sacco et al. suggest that DEP-1 could act on EGFR 
phospho-Tyr998 (Sacco et al., 2009). Tarcic et al. 
suggest a mechanism by which DEP-1 affects EGFR 
trafficking and signaling. They show that DEP-1 
dephosphorylates EGFR at the cell surface and affects 
the major phosphorylation site on CBL (at Tyr731), 
thus hampering EGFR ability to associate with the 
dedicated ubiquitin ligase complex (i.e., CBL-GRB2). 
This blocks EGFR ubiquitinylation, translocation to
endosomes and, consequently, downstream signalling. 
DEP-1 silencing, on the contrary, enhances tyrosine 
phosphorylation of endosomal EGFRs, accelerates 
degradation of EGFR and increases cell proliferation 
(Tarcic et al., 2009). Consistent with this observation 
and with the induction of DEP-1 expression in contact-
inhibited cells, the gene encoding DEP-1 is often 
deleted or mutated in carcinomas (Ruivenkamp et al., 
2003a). 
A genomic analysis of four different DNA samples 
(peripheral blood, primary tumor, brain metastasis and 
an early passage xenograft) from a patient with basal-
like breast cancer (i.e., ERBB2 and ER negative), 
identify a missense mutation (K1017N) in 
DEP1/PTPRJ that is highly enriched during disease 
progression, since it is found enriched in metastasis nd 
in the human-in-mouse xenograft, compared to primary 
tumor (Ding et al., 2010). The mutation site is in the 
juxtamembrane domain (a basic residue motif) and is in 
close proximity to the tyrosine-protein phosphatase 
domain (aa 1041-1298). Sacco et al. reported that the 
DEP-1 charged peptide 1013-IKPKKSKLIRVE-1024 
is responsible for interaction with its substrates, such as 
ERK1/2 (Sacco et al., 2009). The K1017N mutation 
found in the basal tumor and the K1016A mutation 
described in Sacco's report, both describe a change of a 
basic residue into a neutral residue. The DEP-1 
positively charged peptide has a loose resemblance to 
the KIM domains that is essential to bind the common 
docking domain of ERK1/2 proteins. Therefore, a 
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mutation in the DEP-1 KIM domain affects ERK1/2 
recruitment, thus impacting specifically on phospho-
Tyr204 ERK1/2 dephosphorylation efficiency. DEP-1 
can therefore suppress proliferation by sequestering 
ERK1/2, irrespective of ERK1/2 phosphorylation state 
and by dephosphorylating the ERK1/2 activation loop.  
Loss of heterozygosity, and missense mutations in the 
DEP-1 gene have been identified in several human 
cancers including colon, lung, and breast, which have 
also been associated with aberrant Hepatocyte Growth 
Factor Receptor Tyrosine Kinase (Met) signaling. 
Palka et al. identify the hepatocyte growth factor/scatter 
factor receptor Met, the adapter protein GAB1 and the 
junctional component p120 catenin as potential DEP-1 
substrates. Moreover, they show that DEP-1 
preferentially dephosphorylates Met at sites involved in 
Met signaling: a GAB1 binding site (Tyr1349) and a 
COOH-terminal tyrosine implicated in morphogenesis 
(Tyr1365), while leaving unaltered the phosphorylation 
at the Met activation loop (Palka et al., 2003; Wang et 
al., 2010). A phosphatome RNAi (RNA interference) 
screen in A549 cells (lung adenocarcinoma) designed 
to identify phosphatases that behave as key negative 
regulators of oncogenic Ras signalling, characterized 
DEP-1 as a specific inhibitor of oncogenic K-Ras 
activation of Akt. The basis for this may be due to the 
role of DEP-1 in dephosphorylating residues within t e
p85 subunit of PI3K, resulting in attenuated PI3K/Akt 
activation (Omerovic et al., 2010). 
DEP-1 and VEGFR 
Whether or not DEP-1 plays a role in hematologic 
malignancies is not clear. 
DEP1 targets VEGFR2 phospho-tyrosines: In contact-
inhibited endothelial cells, the phosphatase DEP-1, by 
binding beta-catenin and p120, may associate with the 
cadherin-receptor complex and dephosphorylate 
VEGFR-2 that is in complex with VEC (vascular 
endothelial cadherin). Retention of VEGFR-2 at the 
membrane by VEC and its dephosphorylation by DEP-
1 limits its internalization and signaling (Lampugnani 
et al., 2003; Holsinger et al., 2002; Lampugnani et al., 
2006; Lampugnani and Dejana, 2007a; Lampugnani 
and Dejana, 2007b; Dejana et al., 2008). 
Despite its negative role on global VEGFR2 
phosphorylation, DEP-1 is a positive regulator of 
VEGF mediated Src and Akt activation and endothelial 
cell survival.  
In fact, when DEP-1 is depleted, inhibitory Src Y529 
phosphorylation is increased and consequently, Src 
activation is impaired. Reduced Src activity correlat s 
with decreased phosphorylation of GAB1 that cannot 
associate with PI3K (phosphatidylinositol 3-kinase), 
thus impairing AKT activation (Chabot et al., 2009). 
Cogan's syndrome 
Note 
DEP-1 has been implicated in an autoimmune disease, 
the Cogan's syndrome, which is a chronic inflammatory 
disease characterized by sensorineural hearing loss,
keratitis, and vasculitis. A screen for autoantigens i  
this disease revealed antibodies to DEP-1, which is 
expressed on the sensory epithelia of the inner ear and 
on endothelial cells (Lunardi et al., 2002). These 
autoantibodies inhibit proliferation of DEP-1 
expressing cells and can replicate the hearing loss
feature of Cogan's disease, when infused into mice. It is 
not determined whether these antibodies are causative 
for this autoimmune disease and/or others (e.g., 
pseudo-Pendred syndrome) (Davis et al., 2006). 
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